Parabilis Medicines

Parabilis Medicines is a private, preclinical/clinical-stage biotech developing a novel class of stabilized helical peptide therapeutics via its proprietary Helicon platform. This platform combines AI, simulation, and extensive non-canonical amino acid chemistry to create cell-permeable peptides that can inhibit challenging intracellular protein-protein interactions, target proteins for degradation, and deliver radioligands. The company's lead program, zolucatetide, has received FDA Orphan Drug Designation for desmoid tumors, validating its approach to targeting the elusive β-catenin:TCF interaction.

Helicon platform: An AI- and simulation-enabled platform for designing ultra-tunable, alpha-helically locked peptides composed of non-canonical amino acids. It enables the creation of cell-permeable peptides that can inhibit intracellular protein-protein interactions, deliver radioligands, and degrade target proteins.

Parabilis competes in the crowded and innovative space of targeting intracellular protein-protein interactions. Direct competitors include companies developing other stabilized peptides (e.g., stapled peptides), molecular glues, PROTACs/degraders, and other novel modalities. Its success hinges on demonstrating superior drug-like properties, such as cell permeability, specificity, and tunability, compared to these alternative approaches.